Cardano Summit 2025 Concludes In Berlin: Trust Emerges As The Winner with Traditional Financial Firms Feeling Blockchain FOMO
17.11.2025 14:23:00 CET | Business Wire | Press Release
Last week’s Cardano Summit 2025 at Berlin’s iconic Gasometer heard from 140 speakers, brought together close to 800 attendees from over 70 countries, and attracted over 25,000 online participants, showcasing significant momentum in enterprise blockchain adoption.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117496852/en/
Cardano Foundation CEO Frederik Gregaard on the main stage at the Cardano Summit 2025 in Berlin
Across two days of strategic discussions, enterprise leaders joined the Cardano community to discuss industry readiness, DeFi expansion, and the convergence of AI with distributed systems. The Cardano Foundation also outlined its 2026 roadmap highlighting decentralized finance (DeFi) liquidity, Web3 integration, and real-world asset (RWA) tokenization as key focus areas. Additionally, Singapore was unveiled as the location for next year’s Summit.
Cardano Foundation CEO Frederik Gregaard set an ambitious tone as he opened the Summit by addressing the “army of changemakers” in attendance, outlining the critical role of trust in driving blockchain adoption. “Trust is the real value of decentralization,” legendary venture capitalist Tim Draper told the Summit, emphasizing how blockchain enables confidence in data and financial security. This sentiment was echoed by Johnson & Johnson's Florian Krueger-Herbert, who highlighted blockchain's role as a “safe, tamper-proof record that everyone can trust, from manufacturers to patients.”
The launch of the Cardano Foundation’s Blockchain Research Institute report on Digital Trust Infrastructure was a highlight of the Summit. This new framework, designed to reduce friction and boost productivity in the next economy, resonated throughout Day Two discussions, where Christoph Schneider of the Global Legal Entity Identifier Foundation emphasized that businesses have "a lot to gain in this decentralized system.”
The urgency of trust and identity solutions became clear with Thomas Mayfield, Head of Decentralized Trust and Identity Solutions at the Cardano Foundation, noting that “80% of data breaches are due to identity being compromised.” Animoca Brands' Robby Yung described zero-knowledge proofs as a “silver bullet” allowing selective disclosure without compromising privacy.
The Summit also revealed a dramatic shift in traditional finance's blockchain stance. Boston Consulting Group's Bernhard Kronfellner noted that major banks have developed “FOMO,” with “two-thirds of conversations now about stablecoins.” European Commission Principal Economist Joachim Schwerin confirmed the EU's “very positive approach to blockchain,” positioning it as a breakthrough technology. This institutional momentum was reinforced by Mastercard's Christian Rau, who explained that “we have more optionality now than ever with payments,” highlighting stablecoins' capacity to “solve a real issue” beyond cross-border payments, including payroll, treasury management, and DeFi applications.
These key themes and topics resonated with the recently published Cardano Foundation Roadmap which confirmed the Foundation’s continued commitment to its existing mission of Cardano adoption by legacy enterprises, and blockchain-for-good initiatives, while simultaneously outlining plans for increased efforts in the decentralized finance (DeFi) and Web3 sectors. In keeping with its commitment to remain focused on transparency, measurable outcomes, and consistent delivery across each area of the roadmap, a recent update highlighted actions undertaken and work in progress on both the DeFi and Web3 initiatives as well as the RWA, governance decentralization and promotion and education programs.
CEO Frederik Gregaard closed the Summit by positioning blockchain as a global digital trust infrastructure that counterbalances AI's limitations, enabling secure, decentralized identity and resilience against centralization. With enterprise and institutional interest accelerating through “real, behind-closed-doors adoption discussions,” the Foundation's strategic focus toward DeFi and Web3, while staying close to enterprise adoption, reflects the ecosystem's maturation and readiness for mainstream blockchain implementation.
ENDS
Interviews with Cardano Foundation executives are available on request.
About the Cardano Foundation
The Cardano Foundation is an independent, Swiss-based, not-for-profit organization tasked with advancing Cardano as a public digital infrastructure across industries. The Foundation develops infrastructure tooling, strengthens operational resilience, and drives real-world use cases and sound governance. For more information, visit https://cardanofoundation.org
Media kit can be accessed here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251117496852/en/
Contacts
For media inquiries and interview requests, please contact:
cardanosummit@150bond.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom